Reporting of methodologic information on trial registries for quality assessment: a study of trial records retrieved from the WHO search portal by Reveiz, Ludovic et al.
Reporting of Methodologic Information on Trial
Registries for Quality Assessment: A Study of Trial
Records Retrieved from the WHO Search Portal
Ludovic Reveiz1*, An-Wen Chan2, Karmela Krlezˇa-Jeric´3, Carlos Eduardo Granados4, Mariona Pinart5,
Itziar Etxeandia6, Diego Rada7, Monserrat Martinez8, Xavier Bonfill9, Andre´s Felipe Cardona10
1 Research Institute, Sanitas University Foundation, Bogota´, Colombia, 2Women’s College Research Institute, University of Toronto, Women’s College Hospital, Toronto,
Canada, 3 Knowledge Synthesis and Exchange Branch, Knowledge Translation Portfolio, Canadian Institutes of Health Research, Ottawa, Canada, 4 Research Institute,
National University of Colombia, Bogota´, Colombia, 5 Experimental Studies, Airway Disease Section, National Heart and Lung Institute, Imperial College London, London,
United Kingdom, 6Clinical Epidemiology Unit, Cruces Hospital & Osteba-Basque Office for HTA, Department of Health, Bilbao, Spain, 7Unidad de Investigacio´n de
Atencio´n Primaria, Bilbao, Spain, 8 Institut de Recerca Biome`dica de Lleida - Universitat de Lleida, Catalonia, Spain, 9 Servicio de Epidemiologı´a Clı´nica y Salud Pu´blica,
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Clinical and Translational Oncology Group, Fundacio´n Santa Fe de Bogota´, Bogota´, Colombia
Abstract
Background: Although randomized clinical trials (RCTs) are considered the gold standard of evidence, their reporting is
often suboptimal. Trial registries have the potential to contribute important methodologic information for critical appraisal
of study results.
Methods and Findings: The objective of the study was to evaluate the reporting of key methodologic study characteristics
in trial registries. We identified a random sample (n = 265) of actively recruiting RCTs using the World Health Organization
International Clinical Trials Registry Platform (ICTRP) search portal in 2008. We assessed the reporting of relevant domains
from the Cochrane Collaboration’s ‘Risk of bias’ tool and other key methodological aspects. Our primary outcomes were the
proportion of registry records with adequate reporting of random sequence generation, allocation concealment, blinding,
and trial outcomes. Two reviewers independently assessed each record. Weighted overall proportions in the ICTRP search
portal for adequate reporting of sequence generation, allocation concealment, blinding (including and excluding open label
RCT) and primary outcomes were 5.7% (95% CI 3.0–8.4%), 1.4% (0–2.8%), 41% (35–47%), 8.4% (4.1–13%), and 66% (60–72%),
respectively. The proportion of adequately reported RCTs was higher for registries that used specific methodological fields
for describing methods of randomization and allocation concealment compared to registries that did not. Concerning other
key methodological aspects, weighted overall proportions of RCTs with adequately reported items were as follows:
eligibility criteria (81%), secondary outcomes (46%), harm (5%) follow-up duration (62%), description of the interventions
(53%) and sample size calculation (1%).
Conclusions: Trial registries currently contain limited methodologic information about registered RCTs. In order to permit
adequate critical appraisal of trial results reported in journals and registries, trial registries should consider requesting details
on key RCT methods to complement journal publications. Full protocols remain the most comprehensive source of
methodologic information and should be made publicly available.
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Introduction
Critical appraisal of randomized clinical trials (RCTs) relies on
the availability of adequate information about study design and
conduct. Based on methods described in published journal articles,
RCTs are often considered to be ‘‘inadequately reported’’ or to
have ‘‘high or unclear risk of bias’’ depending on the instruments
used to evaluate them [1]. Therefore, even if an RCT has been
well-designed and conducted, a lack of adequate reporting in the
publication may decrease its perceived quality and strength of
evidence for guiding clinical practice [1,2].
Full protocols are a particularly valuable source of information
about the design and conduct of RCTs [1,3]. However, given that
protocols are often not publicly available, trial registries currently
constitute the main public source of basic protocol information.
The number of registries and registered clinical trials has been
increasing since 2004, after the requirement for public registration
at study inception was introduced by the International Committee
of Medical Journal Editors (ICMJE) [4–7]. There is general
agreement about the minimum protocol information that should
be registered for a trial, as defined by the 20-item World Health
Organization (WHO) Registration Data Set [8]. However, the
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limited methodologic information contained in the WHO data set
does not permit full appraisal of trial quality. The ICMJE
statement [4] expressed that even if acceptable completion of data
fields was an important concern, many entries in a publicly
accessible registries did not provide meaningful information in
some key data fields. The World Health Organization Interna-
tional Clinical Trials Registry Platform (ICTRP) considers that the
registration of ongoing trials is useful among others because it
‘‘may lead to improvements in the quality of clinical trials by
making it possible to identify potential problems (such as
problematic randomization methods) early in the research
process’’ (http://www.who.int/ictrp/trial_reg/en/index.html).
Although some registries have included additional items to
improve the reporting of the trials, those items are not compulsory.
Consequently, there is a gap between the WHO 20-items and the
information needed to adequately appraise a trial. For example,
the WHO data set contains a specific item for the ‘‘study type’’
which should include the type of study (interventional or
observational) and details on the study design (method of
allocation, masking, methods of randomization and the phase (if
applicable) [8]. However it is unclear how much detail should be
reported on methods of randomization, allocation concealment
and blinding. This is understandable because trial registries were
initially conceived to identify the existence of a trial and not to
provide all the required information concerning methodological
issues.
However, in addition to the overall benefits of increased
transparency and identification of suppressed trial results, registries
have the potential to provide valuable methodologic information
that is necessary for critical appraisal of trial results. Given the
recent policies mandating public disclosure of results for relevant
registered trials [9,10], information on trial methods will be
increasingly important to reliably interpret the trial results.
We assessed the quality of methodological information available
for ongoing RCTs registered in six WHO Primary Registries and
ClinicalTrials.gov in 2008.
Methods
We used the WHO/ICRTP (ICTRP) Search Portal to identify
a random sample of RCTs registered from January 1 to December
12, 2008 and open for recruitment on December 12, 2008. At the
time of our study, the ICTRP Search Portal provided access to
data from ClinicalTrials.gov and six WHO primary registries
(Australian New Zealand Clinical Trials Registry (ANZCTR), the
Chinese Clinical Trial Register, the Clinical Trials Registry -
India, the German Clinical Trials Register, International Standard
Randomised Controlled Trial Number Register (ISRCTN), and
the Netherlands National Trial Register). Each record was
screened by one reviewer (LR) to identify RCTs. The record
was included if it explicitly used the word ‘random’ or variations
thereof to describe the allocation method.
We extracted data on key methodologic items from each
registry record using an evidence based source to define domains
developed by the Cochrane Collaboration [1]. The tool consists of
six domains (sequence generation, allocation concealment, blind-
ing, incomplete outcome data, selective outcome reporting and
‘other issues’) for assessing the quality of an RCT based primarily
on published reports. The description of each domain provides a
general risk of bias in the included randomized trials as well as any
important flaws in the studies [1]. Although some domains can
only be evaluated once the trial is published, others are relevant at
the registration stage and were designated as the primary
outcomes of our study: the proportions of RCT records with
adequate reporting of the methods of random sequence genera-
tion, allocation concealment, blinding and outcomes (primary,
secondary, and harms outcomes). While harms can be primary or
secondary outcomes, we decided to collect specific information on
harms because they are frequently underreported. We also
evaluated descriptions of the follow-up period, trial interventions
and sample size calculations. For each methodological item, we
defined adequate reporting based on the Cochrane Collaboration
Risk of Bias tool [1], the Consolidated Standards of Reporting
Trials (CONSORT) [11], the WHO Trial Registration Data Set
(http://www.who.int/ictrp/network/trds/en/index.html) and the
instructions for registrants provided by registries (Table 1). An item
was classified as inadequately reported if the reporting was unclear
(i.e. some useful information provided, but insufficient detail to
meet the definition of adequacy) or absent (i.e. no useful
information provided) (Table 1). Finally, we also collected
information on the type of intervention (drugs, procedures,
behavior/education, devices, vaccines, and combined) and the
type of funding (industry versus non-industry).
The total number of records for all study designs is shown in
Table 2. The ICTRP search portal does not differentiate records
of RCTs from other study designs. We therefore estimated that
50% of these trial records were RCTs based on a random pilot
sample of 100 records, as well an advanced search strategy using
the word ‘random’ or variations thereof in the title or intervention
field of all records from the ICTRP search portal. We sought to
ensure adequate representation across registries by including all
available RCTs from those registries with few records (the
Chinese, Indian and German registries). For each of the other
registries, we estimated the proportion of RCTs with adequate
reporting of random sequence generation or allocation conceal-
ment to be less than 12% based on a pilot sample of 100 records.
We then calculated the sample size required for each of these
larger registries to yield an estimated prevalence of adequate
reporting with 95% confidence, 80% power and 7% precision
(Table 2). Each record in the sample was screened to ensure that it
was an RCT (the word ‘random’ or variations thereof). For RCTs
that were registered on multiple registries, we randomly selected
only one record for inclusion.
Two independent reviewers extracted information from each
trial, with discrepancies resolved by discussion with a third
evaluator. Five of the seven data extractors participated in an
advanced method of systematic review course organized by the
Ibero-American Cochrane Centre in Madrid and therefore
received the same training on the Cochrane Collaboration Risk
of Bias tool and other issues of RCT assessment. The two
evaluators had experience in the used the Cochrane tool. Data
were analyzed descriptively as weighted and raw proportions using
SPSS 15.0, and Chi-square tests were used to determine
associations between categorical variables.
Results
From the 7 clinical trial registries, we included a total of 265
RCT records with principal registrants from 35 countries. In terms
of blinding, 141 RCTs were reported as blinded (53%), 101 as
open label (38%) and 23 (9%) records contained insufficient
information for judgment; four trials had one open label arm and
one blinded arm. The types of interventions included drugs (60%),
procedures (15%), behavior modification/education/counseling
(13%), devices (4.2%), and combination of interventions -e.g. drug
vs. procedure- (4%), vaccines (1.1%), and other (2.3%).
Overall, the proportion of adequate reporting varied by
methodologic item from the Cochrane Collaboration Risk of Bias
Usefulness of Trial Registries
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tool: random sequence generation (weighted proportion 5.7%,
95% CI 3.0–8.4%), allocation concealment (1.4%, 0–2.8%),
blinding (41%, 35–47% including open label RCTs; 8.4%, 4.1–
13% excluding open label RCTs), primary outcomes (66%, 60–
72%), secondary outcomes (46%,40–52%) and harms outcomes
(5%, 2–8%) (Table S1). Weighted proportions were calculated
using data from Table 2. Most records reported no useful
information for allocation concealment (97.9%) and harm
(89.5%), and had insufficient detail for blinding (86.2%, excluding
open label RCTs) and primary outcome measures (32%). One
record stated that the trial was blinded in the Methods section and
open in the Summary section. Examples of adequate and unclear
reporting are shown in Table 3.
Concerning other methodological items, weighted overall
proportions of trial records with adequately reported items were
variable (Table S2). Adequate reporting of eligibility criteria,
follow up duration and study interventions were 81%, 62% and
53% respectively. Reporting of details of sample size calculations
was particularly poor, with adequate descriptions in only 1% of
records. Although the target sample size was reported for 97% of
trials, the number of participants in each study arm was stated in
only 7%. Only four records provided a link to the full study
protocol.
Reporting of methodologic items varied substantially across
registries, with two registries (Australian New Zealand Clinical
Trials Registry and the Clinical Trials Registry – India) having
Table 2. Identification of study sample based on total number of recruiting studies and estimated number of RCTs registered from
January 1 to December 12, 2008.
Trial registry Number of recruiting studies
Weight of estimated number of
RCTs in the ICTRP search portal
Number of recruiting RCTs
included in our study sample
ANZCTR 226 2.4% 49
Chinese Clinical Trials register 71 0.1% 6
Clinical Trial Registry-India 45 0.5% 21
Clinicaltrials.gov 8503 89.6% 81
German Clinical Trials Register 10 0.1% 5
ISRCTN 541 5.7% 63
Netherlands NTR 153 1.6% 40
Total 9549 100% 265
doi:10.1371/journal.pone.0012484.t002
Table 1. Criteria for defining adequate reporting.
Item Criteria
Sequence generation Description of the process used to generate the random allocation sequence, such as:
1. Referring to a random number table; 2. Using a computer random number generator; Coin tossing; Shuffling cards or envelopes;
Throwing dice; 3. Drawing of lots; Minimization.
Allocation concealment Description of the method used to conceal the allocation sequence from participants and investigators such that it could not be
predicted in advance (e.g., Central allocation (including telephone, web-based and pharmacy-controlled randomization); sequentially
numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).
Blinding 1. Explicit statement that the study is open label; or 2. For blinded studies, all of the following: a) A description of who was masked: the
individuals receiving the treatment/s;the individuals administering the treatment/s; the individuals assessing the outcomes; the
individuals analysing the results/data b) Complete description ensuring that blinding could not be broken (e.g., ‘‘double blind, double
dummy’’; ‘‘tablets or capsules are indistinguishable in all aspects of their outward appearance’’)
Primary and secondary
outcomes
Specific variable, metric, and measurement timepoints of interest for all primary outcomes (e.g., ‘‘% with Beck depression score .10 at 6
months’’ rather than just ‘‘depression’’).
Harms outcomes Description of outcomes related to adverse events and abnormalities of laboratory tests (laboratory-determined toxicity), as well as the
procedure to collect the information: Specific variables and timepoints of collection for harms were provided Instrument(s) to be used
for the assessment/ measurement, where possible.
Follow-up duration Explicit statement of the length of follow-up. When the outcome is time to an event, the follow-up duration is variable for each
participant and may not be specifically known.
Interventions Specific names of the interventions assigned to trial participants, and a description of other relevant intervention details as applicable
(e.g., dose, duration, mode of administration, etc)
Sample size calculation Description of key elements of the sample size calculation: The outcome variable used; The alpha (Type I) error level and the statistical
power (or the beta [Type II] error level); The clinically important difference between the intervention groups; For binary outcomes, the
estimated results in each group; For continuous outcomes, the variance, standard deviation or standard error of the measurements.
Number of participants
in each arm
The number of participants in each arm.
Inclusion and exclusion
criteria
Explicit definition of eligibility criteria, including age and sex.
doi:10.1371/journal.pone.0012484.t001
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higher proportions of trials with adequate reporting of most items
than the others (Table S1).
Characteristics of the data entry fields also varied across clinical
trial registries (Tables S1 and S2). The proportion of specific fields
for all 11 methodologic items ranged from 37% (4/11) to 82% (9/
11) within each registry. ANZCTR, Clinical Trials Registry –
India, and the Chinese Clinical Trial Register were the only
registries that offered specific fields for random sequence
generation and allocation concealment. Few registries provided
fields for reporting sample size calculations (Clinical Trials
Registry – India) or the planned number of participants in each
study arm (Chinese Clinical Trial Register).
27% of RCTs from the sample were funded by industry.
Clinicaltrials.gov contained a significantly higher proportion of
industry funded RCTs compared to the WHO Primary Registries
(43% vs. 20%; p,0.001). In an exploratory analysis, no significant
differences were found for adequate reporting of random sequence
generation, allocation concealment, blinding and primary out-
comes between industry and non-industry RCTs. We found no
significant difference in adequate reporting of study interventions




A key obstacle in the assessment of trial quality is the lack of
available information about study design and conduct [1,12].
Despite important initiatives to improve reporting, such as
CONSORT [10], methodologic descriptions in trial publications
often provide inadequate detail and do not necessarily reflect the
way the trial was conducted [2]. Trial registries offer an added
source of protocol information to complement journal publications
and to track the existence of an RCT. There is general agreement
about the minimum protocol information that should be registered
for a trial, as defined by the 20-item WHO Registration Data Set
[8] supported by ICMJE, other medical journals [13] and the
Ottawa group [12]. However, our findings reveal that the amount
of methodologic information available for critical appraisal of a
trial is low overall and varies between registries. Our results are
consistent with previous literature demonstrating that the WHO
Registration Data Set items are often incompletely registered by
trialists and do not encompass key aspects of trial design and
planned conduct [14–18]. Nonetheless, when adequately reported,
the information available in registries can be useful to evaluate the
risk of bias and other key methodological aspects related to
internal and external validity.
There are various possible explanations for the low prevalence
of adequate reporting. A number of the assessed items (i.e.
allocation concealment, method of randomization, sample size
calculations) are not explicitly part of the WHO 20-item Trial
Registration Data Set (TRDS) or ICMJE requirements [4,8].
Although they are not mandatory items for the registries included
in the study, they are essential for assessing the quality and the risk
of bias of RCTs [1,11]. To encourage registration in these early
years, most registries have focused on ensuring adherence to the
20 WHO TDRS items. However, our findings are helpful in
highlighting the lack of information for other essential items or a
more detailed description of the TRDS items.
Clearly if there is no field for a given item on the registry, then it
cannot be recorded. This was most relevant for reporting of
sample size calculations and the number of participants in each
study arm. The reporting of key methodological information is
also influenced in part by the way registries asks registrants to enter
their data. For example, the ANZCTR, the Indian and Chinese
Clinical Trials Registries –have specific fields for describing the
methods of randomization and allocation concealment whereas
other registries have general (‘‘Methods’’ Fields) or restrictive
coded fields (restricted to randomized, non-randomized, observa-
tional etc). Most registries offer specific coded fields for blinding
(open label, single blind or double blind) or a description of
masked roles (subject, caregiver, investigator, outcomes assessor).
However, a specific free text field or a more detailed coded field is
not available to allow a more detailed description of how blinding
was achieved.
In a cross-section of trials registered at ClinicalTrials.gov, Ross
et al reported that nearly 100% of ClinicalTrials.gov records
provided mandatory data elements (title, sponsor, condition
studied, design, type, phase, and intervention and population
studied), although the quality of information was not assessed.
Table 3. Examples of adequate and unclear reporting.
Item Adequate reporting Unclear reporting
Sequence generation: ‘‘Randomization table using computer software’’ ‘‘Randomization’’
Allocation concealment: ‘‘Central randomization by computer’’; ‘‘Sequentially
numbered, sealed, opaque envelopes’’
‘‘Sealed envelopes’’; ‘‘Envelopes’’
Blinding: ‘‘Blinded/ masking used’’; and who is blinded: ‘‘The people
receiving the treatment’’… ‘‘administering the treatments’’
‘‘assessing the outcomes’’ ‘‘analyzing the results’’…’’placebo
oral tablets designed to look, smell and taste similar than…’’,
‘‘Blind’’; ‘‘Single blind’’
Interventions: ‘‘Finasteride 5 mg PO once daily for 8 weeks…’’ ‘‘Levofloxacin’’ vs. ‘‘gentamicin’’; ‘‘Treatment as usual’’ vs.
‘‘Behavioral: case management’’; ‘‘Stress’’ vs. ‘‘no-stress’’
Outcomes: ‘‘Progression-free survival which is measured by regular CT
(computerised tomography) scans prior to treatment, every
six weeks during chemotherapy, and every two months after
chemotherapy until the lung cancer has progressed
Timepoint: After 460 progression events have occurred over
all of the participants in the study (after 460 patients have
shown progression of their lung cancer)’’
‘‘Morbidity of chemotherapy and surgery’’; ‘‘The primary
and secondary outcome measures will be measured
after the completion of the trial.’’ (no further details);
‘‘Improvement in metabolic profile and histology at 6
months’’
Eligibility criteria --- ‘‘Patients with symptomatic atrial fibrillation..’’ and
‘‘other inclusion criteria’’
doi:10.1371/journal.pone.0012484.t003
Usefulness of Trial Registries
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Conversely, reporting of optional data elements varied (66% for
primary outcome measures; 56% for secondary outcome mea-
sures) [19].
There were important differences among those registries that
incorporated key methodological fields and those that did not. We
found that registries having specific fields for some items obtained
more relevant information for critical appraisal than registries with
general open and or coded fields. Registries should consider
including specific data entry fields to record methodologic items
that have been associated with bias [1]. It seems that specific fields
for certain domains (e.g. ‘‘describe the allocation concealment
procedure’’) have more impact than open fields (e.g. ‘‘describe
methods’’). The usefulness of the information for the public,
clinicians, systematic reviewers, and other stakeholders interested
in trial results could be improved by including a few additional
methodologic fields.
Another reason for poor reporting on registry records is that the
information may not even available in the source document, the
full protocol. Previous studies have shown that methodologic
information is often inadequately described in RCT protocols
[20–25]. In addition, if the individuals registering the trial have an
administrative rather than a scientific background, they may not
have sufficient methodologic knowledge to properly register the
information.
To complement the limited methodologic information available
on trial registries, the Ottawa Statement (http://ottawagroup.ohri.
ca.) and others have recommended public disclosure of the full
protocol to enable reliable interpretation of trial findings
[3,12,26,27]. However, few protocols are currently publicly
available and their content is variable. To improve transparency,
the SPIRIT initiative (Standard Protocol Items for Randomized
Trials) has been developing evidence-based recommendations on
the essential information to describe in protocols [28]. With the
recent move towards mandatory registration and results disclosure
on public databases [9,10,29] and ongoing discussion regarding
international standards such as PROCTOR (Public Reporting of
Clinical Trial Outcomes and Results) [30], improved public
availability of methodologic information will become increasingly
important to place results into their proper context.
Study limitations
Due to technical limitations of the databases and duplicate
registrations, it was not possible to determine exactly the total
number of RCTs in the registries without manually reviewing all
9549 records registered during our study period. We thus had to
estimate the total number of RCTs based on a pilot sample. It is
unlikely that our calculation of weighted proportions would have
been significantly affected by any inaccuracy, since the vast
majority of records were from one registry (ClinicalTrials.gov).
Another limitation is that the assessment of some items was
inherently subjective. For example, assessment of reporting of
eligibility criteria was limited by data extractors not being
intimately familiar with the clinical topic of every RCT. In some
cases, it was also difficult to determine adequate reporting for non-
drug interventions (i.e. surgery, education, counselling, devices).
However, we used a low threshold to classify records as adequately
reported for these uncertain circumstances. We also used duplicate
data extraction to reduce bias, and involved a third individual
when necessary.
Conclusion
Reporting of methodologic information on trial registries has
not been a focus of early registration requirements, and
consequently the quality of reporting of trial methods in registry
records is poor overall. It is imperative that disclosure of trial
results in public databases or journal publications be accompanied
by sufficient methodologic information to fully appraise them.
Considering that widespread implementation of trial registration is
relatively recent, registries can continue to learn from each other,
from empiric studies, and from their own internal evaluations to
improve the reporting of trial methods. Full trial protocols remain
a key source of methodologic information, and should be made
publicly available.
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